Skip to content
Evigrade
CriticalAntiretroviral, HIV protease inhibitor×Antiepileptics. Carboxamide derivatives

Updated · Methodology

Mechanism

Carbamazepine is a strong inducer of the enzyme CYP3A4 and other liver enzymes and can lower the levels of drugs cleared mainly by CYP3A4 (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The liver breaks down atazanavir through CYP3A4, and the atazanavir documents class carbamazepine as a strong inducer of this enzyme. Atazanavir levels may fall, human immunodeficiency virus (HIV) treatment may lose its effect, and the virus may become resistant (atazanavir SmPC, European Medicines Agency, EMA, and atazanavir label, US Food and Drug Administration, FDA). Atazanavir boosted with cobicistat is even more sensitive to this induction (atazanavir/cobicistat SmPC, EMA). The effect also runs the other way: atazanavir inhibits CYP3A4, the enzyme that converts carbamazepine to its active metabolite, and can raise carbamazepine levels (atazanavir SmPC, EMA, and FDA label; carbamazepine SmPC, AEMPS).

Symptoms

The fall in atazanavir levels causes no symptoms by itself: antiviral treatment loses its effect, the human immunodeficiency virus (HIV) viral load rises, and the virus may become resistant (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA, and atazanavir label, US Food and Drug Administration, FDA). This shows only on blood tests. Atazanavir can raise carbamazepine levels (atazanavir SmPC, EMA), and high carbamazepine levels can cause dizziness, drowsiness, ataxia and double vision (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Stopping carbamazepine abruptly can trigger seizures (carbamazepine SmPC, AEMPS).

Management

The combination is contraindicated. The atazanavir documents name carbamazepine among the strong CYP3A4 inducers that are contraindicated with atazanavir, both with and without ritonavir (atazanavir and atazanavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA; atazanavir label, US Food and Drug Administration, FDA). The carbamazepine SmPC does not name atazanavir. It lists human immunodeficiency virus (HIV) protease inhibitors both among the drugs that raise carbamazepine levels and among the drugs whose effect carbamazepine can reduce or even abolish. With such combinations, adjust the doses and monitor carbamazepine levels (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For a person taking atazanavir, choose seizure treatment without carbamazepine, phenytoin or phenobarbital (atazanavir SmPC, EMA, and FDA label). No document gives an interval between stopping carbamazepine and starting atazanavir. Do not stop carbamazepine abruptly, as seizures may follow: withdraw it gradually over 6 months. If carbamazepine has to be stopped abruptly in a person with epilepsy, switch to another antiepileptic under the cover of a suitable drug, such as intravenous or rectal diazepam (carbamazepine SmPC, AEMPS). The interaction table of the same atazanavir SmPC still contains a softer entry that advises caution with carbamazepine. The contraindications section of this SmPC is stricter (atazanavir SmPC, EMA). If the two drugs have nevertheless been taken together, monitor the virological response closely, and check carbamazepine levels and adjust its dose if needed (atazanavir SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Atazanavir

Other interactions with Carbamazepine